Association between levothyroxine replacement therapy and osteoporosis in Riyadh, Saudi Arabia: a matched case-control study.

IF 1.5 4区 医学 Q4 CHEMISTRY, MEDICINAL Pharmazie Pub Date : 2022-10-01 DOI:10.1691/ph.2022.2436
Haifa F Alotaibe, L A Alolaiwi, A Almutairi, N Alsubaie, M Badri, M F Balaha, E-S Khafagy, Hadil F Alotaibi
{"title":"Association between levothyroxine replacement therapy and osteoporosis in Riyadh, Saudi Arabia: a matched case-control study.","authors":"Haifa F Alotaibe,&nbsp;L A Alolaiwi,&nbsp;A Almutairi,&nbsp;N Alsubaie,&nbsp;M Badri,&nbsp;M F Balaha,&nbsp;E-S Khafagy,&nbsp;Hadil F Alotaibi","doi":"10.1691/ph.2022.2436","DOIUrl":null,"url":null,"abstract":"<p><p>Hypothyroidism is a common health problem among elder women. However, conflicting results were observed regarding the association between levothyroxine treatment and osteoporosis risk. Therefore, the current study aimed to evaluate the effect of levothyroxine replacement therapy on osteoporosis risk in the Saudi population. This study was a matched case-control study conducted from June to August 2020. Data were extracted from the electronic medical records and included sociodemographic, clinical characteristics, comorbid conditions, levothyroxine replacement therapy dose, duration, concomitant therapy, and bone mineral density. Cases were matched with controls (1:1 basis) by age; the study included 256 cases and 256 controls. In the multivariate conditional logistic regression analysis, thyroxine use was independently associated with an increased likelihood of osteoporosis. Therefore levothyroxine use in elderly females was associated with an increased risk of osteoporosis, and hence, clinicians must be aware of the levothyroxine replacement therapy outcomes in postmenopausal females at risk of osteoporosis.</p>","PeriodicalId":20145,"journal":{"name":"Pharmazie","volume":"77 10","pages":"295-298"},"PeriodicalIF":1.5000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmazie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1691/ph.2022.2436","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Hypothyroidism is a common health problem among elder women. However, conflicting results were observed regarding the association between levothyroxine treatment and osteoporosis risk. Therefore, the current study aimed to evaluate the effect of levothyroxine replacement therapy on osteoporosis risk in the Saudi population. This study was a matched case-control study conducted from June to August 2020. Data were extracted from the electronic medical records and included sociodemographic, clinical characteristics, comorbid conditions, levothyroxine replacement therapy dose, duration, concomitant therapy, and bone mineral density. Cases were matched with controls (1:1 basis) by age; the study included 256 cases and 256 controls. In the multivariate conditional logistic regression analysis, thyroxine use was independently associated with an increased likelihood of osteoporosis. Therefore levothyroxine use in elderly females was associated with an increased risk of osteoporosis, and hence, clinicians must be aware of the levothyroxine replacement therapy outcomes in postmenopausal females at risk of osteoporosis.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在沙特阿拉伯利雅得,左旋甲状腺素替代治疗与骨质疏松症的关系:一项匹配的病例对照研究。
甲状腺功能减退是老年妇女常见的健康问题。然而,关于左旋甲状腺素治疗与骨质疏松风险之间的关系,观察到相互矛盾的结果。因此,本研究旨在评估左旋甲状腺素替代疗法对沙特人群骨质疏松风险的影响。本研究是一项匹配的病例对照研究,于2020年6月至8月进行。数据从电子病历中提取,包括社会人口统计学、临床特征、合并症、左旋甲状腺素替代治疗剂量、持续时间、伴随治疗和骨密度。病例按年龄与对照(1:1)匹配;该研究包括256例病例和256例对照。在多变量条件logistic回归分析中,甲状腺素的使用与骨质疏松症的可能性增加独立相关。因此,在老年女性中使用左旋甲状腺素与骨质疏松症的风险增加有关,因此,临床医生必须了解绝经后有骨质疏松症风险的女性左旋甲状腺素替代治疗的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmazie
Pharmazie 医学-化学综合
CiteScore
3.10
自引率
0.00%
发文量
56
审稿时长
1.2 months
期刊介绍: The journal DiePharmazie publishs reviews, experimental studies, letters to the editor, as well as book reviews. The following fields of pharmacy are covered: Pharmaceutical and medicinal chemistry; Pharmaceutical analysis and drug control; Pharmaceutical technolgy; Biopharmacy (biopharmaceutics, pharmacokinetics, biotransformation); Experimental and clinical pharmacology; Pharmaceutical biology (pharmacognosy); Clinical pharmacy; History of pharmacy.
期刊最新文献
Analysis of progression-free and overall survival in ovarian cancer: Bevacizumab treatment outcomes using historical cohort. Comparison of pharmacotherapeutic analgesic response and safety profile of tapentadol with other opioids. Cross-reactivity of triptans and sulfonamide antibiotics - a clinically relevant question? Impact of medication reconciliation and medication reviews on the incidence of preventable adverse drug reactions during hospitalization of elderly patients. A randomized controlled trial. Potential effects of attention deficit hyperactivity disorder medication on body height and body weight in a longitudinal pediatric cohort study, the LIFE Child study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1